This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Litak is indicated for the treatment of hairy-cell leukaemia.
Therapeutic Area (MeSH)
ATC Code
L01BB04
ATC Item
cladribine
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Cladribine | N/A | 克拉屈滨 |
EMA Name
Litak
Medicine Name
Litak
Aliases
N/ANo risk management plan link.